<DOC>
	<DOCNO>NCT00674310</DOCNO>
	<brief_summary>The objective study ass single dose bioequivalence Roxane 's Ropinirole tablets,0.25 mg , ReQuip Tablets , 0.25 mg ( GlaxoSmithKline ) feed condition use single dose , randomize , 2-treatment , 2-period , 2-sequence cross-over design .</brief_summary>
	<brief_title>A Single-Dose , 2-Period , 2-Treatment , 2-Way Crossover Bioequivalency Study Ropinirole 0.25 mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>The objective study ass single dose bioequivalence Roxane 's Ropinirole tablets,0.25 mg , ReQuip Tablets , 0.25 mg ( GlaxoSmithKline ) feed condition use single dose , randomize , 2-treatment , 2-period , 2-sequence cross-over design .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>No clinically significant abnormal find physical examination , medical history , clinical laboratory result screen Positive test HIV , Hepatitis B , Hepatitis C. Treatment know enzyme alter drug . History allergic adverse response ropinirole comparable product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>